李静雅

个人信息：

李静雅 博士

研究员，国科大杭州高等研究院

浙江省杭州市西湖区象山支路1号 310012

E-mail: jyli@simm.ac.cn

教育背景：

1994-1998，华东师范大学生物系，学士学位

1998-2003，中国科学院上海药物研究所，博士学位

工作经历：

2003-至今，中国科学院上海药物研究所

研究方向：

研究方向为营养环境等因素所致代谢性疾病的病理机制和治疗策略研究。围绕“代谢性疾病中的线粒体稳态失衡”这一关键科学问题，开展新病理机制、新靶标论证和新候选药物等研究。

代表性研究成果：

1.DRAK2 suppresses autophagy by phosphorylating ULK1 at Ser56 to diminish pancreatic β cell function upon overnutrition Science Translational Medicine 2024

2.Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia Acta Pharmaceutica Sinica B 2023, 13(2):739-7533.Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction. Kidney International 2021, 101:315-330

4.DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metabolism 2021, 33:2004-2020

5.DOT1L regulates thermogenic adipocyte differentiation and function via modulating H3K79 methylation. Diabetes 2021,70:1317-1333

6.Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death &Disease, 2019,10:468.

7.SIRT5 regulates brown adipocyte differentiation and browning of subcutaneous white adipose tissue. Diabetes 2019, 68: 1449-1461.8.Mitochondrial uncoupling coordinated with PDH activation safely ameliorates hyperglycemia via promoting glucose oxidation. Diabetes 2019, 68:2197-2209.